Primo Biotechnology Secures A Funding and Targets 2026 IPO to Strengthen Global Radiopharmaceutical Strategy

TAIPEI, Taiwan, July 02, 2025 (GLOBE NEWSWIRE) -- Primo Biotechnology Co., Ltd., a pioneering radiopharmaceutical company in Taiwan, announced the successful completion of its NT$220 million Series A funding round. With total capital raised now exceeding NT$500 million, including seed and early-stage investments, Primo is accelerating its path toward leadership in radioligand theranostics. The company also revealed plans to launch its IPO in 2026, leveraging public market resources to expand R&D capabilities and international reach.

Dr. Ya-Yao Huang, CEO and Co-founder of Primo Biotechnology noted, "Since our founding Primo has been dedicated to developing the next generation of Radioligand Theranostics (RLT) to fight cancer through cutting-edge precision medicine. In April, our radiopharmaceutical facility received dual international certifications in PIC/S GMP and GDP, underscoring our commitment to the highest standards in drug quality. This ...